peptidylprolyl isomerase like 1 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored PPIL1P1 profile across patient tissues and cancer cell-line models. PPIL1P1 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in ESCA. Among the 18 cancer types available for tumor–normal comparison, PPIL1P1 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, PPIL1P1 RNA expression shows 6,819 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ESCA, LUAD, and STAD as cancer lineages where PPIL1P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPIL1P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPIL1P1 survival associations across molecular data types. PPIL1P1 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPIL1P1 RNA expression–survival associations across cancer types. High PPIL1P1 expression shows unfavorable associations in ACC, SKCM, KIRP and SARC, but favorable associations in ESCA and BLCA. The ESCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .011). Together, the overview and detailed table identify ESCA as the clearest survival context for PPIL1P1 RNA expression.
This table summarizes PPIL1P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for PPIL1P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPIL1P1 shows lower tumor expression in LUAD and THCA and higher tumor expression in KIRC. The LUAD box plot shows higher PPIL1P1 RNA expression in normal versus tumor tissue (log2 FC = −0.060, t-test p = .012).
This table shows molecular features associated with PPIL1P1 in patient tissues and cancer cell lines. In patient samples, PPIL1P1 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
